Update on the prevention of type 2 diabetes

Current Diabetes Reports

Volumn 11, Issue 1, 2011, Pages 56-63

  Karam, Jocelyne G ^a   McFarlane, Samy I ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Diabetes; Impaired fasting glucose; Impaired glucose tolerance; Prediabetes; Prevention

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BEZAFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; VALSARTAN; VOGLIBOSE;

ARTICLE; BARIATRIC SURGERY; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES CONTROL; DRUG MECHANISM; DRUG WITHDRAWAL; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW FAT DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREGNANCY DIABETES MELLITUS; RISK FACTOR; RISK REDUCTION; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; EXERCISE; GLUCOSE INTOLERANCE; HUMANS; PREDIABETIC STATE; RISK FACTORS; WEIGHT LOSS;

EID: 79551538263     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0163-x     Document Type: Article

References (62)

1. World Health Organization (WHO). Fact Sheet No 312 November 2009. Available at http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed on September 30, 2010.
2. -2007 National Diabetes Fact Sheet available at http://www.cdc.gov/nchs/ fastats/diabetes.htm. Accessed on September 30, 2010.
3. S Wild G Roglic A Green, et al. 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 1047 1053 10.2337/diacare.27.5.1047 15111519 (Pubitemid 38579764)
4. A Farag J Karam J Nicasio SI McFarlane 2007 Prevention of type 2 Diabetes: An Update Current Diabetes Reports 7 200 207 1:CAS:528: DC%2BD2sXhtVentbrL 10.1007/s11892-007-0032-4 17547837 (Pubitemid 46957283)
5. J Dormandy B Charbonnel D Eckland, et al. 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial in macrovascular Events): a randomized controlled trial Lancet 366 9493 1279 1289 1:CAS:528:DC%2BD2MXhtVOlu7fO 10.1016/S0140-6736(05)67528-9 16214598 (Pubitemid 41416583)
6. SI McFarlane SJ Jacober N Winer, et al. 2002 Control of Cardiovascular Risk factors in patients with diabetes and hypertension of urban academic medical centers Diabetes Care 25 718 723 10.2337/diacare.25.4.718 11919131 (Pubitemid 41071193)
7. SI McFarlane JR Sowers 2005 Gender disparities in the control of cardiovascular risk factors in people with diabetes J Clin Hypertens (Greenwich) 7 383 385 10.1111/j.1524-6175.2005.04124.x
8. AH Mokdad ES Ford BA Bowman, et al. 2003 Prevalence of obesity, diabetes, and obesity-related health risk factors 2001 JAMA 289 1 76 79 10.1001/jama.289.1.76 12503980 (Pubitemid 36026281)
9. JR Sowers M Epstein ED Frolich 2001 Diabetes, hypertension and cardiovascular disease: an update Hypertension 37 1053 1059 1:CAS:528: DC%2BD3MXjtFejt7g%3D 11304502
10. A Hussain B Claussen A Ramachandran, et al. 2007 Prevention of type 2 diabetes: A review Diab. Res. Clin. Pract 76 3 317 326 1:STN:280: DC%2BD2s7ptl2qsQ%3D%3D 10.1016/j.diabres.2006.09.020 (Pubitemid 46505039)
11. •• American Diabetes Association: Standards of Medical Care in Diabetes - 2010. Diabetes Care 2010. 33:S11-61. This paper summarizes the most recent American Diabetes Association (ADA) guidelines of diagnosing diabetes and prediabetes and includes a section on identifying and managing the population at risk of developing diabetes.
12. Cdc.gov/diabetes/pubs/general07.htm
13. DM Nathan MB Davidson A DeFronzo, et al. 2007 Impaired fasting glucose and impaired glucose tolerance: implications for care Diabetes Care 30 3 753 758 1:CAS:528:DC%2BD2sXjs1GrurY%3D 10.2337/dc07-9920 17327355 (Pubitemid 46354366)
14. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354(9179):617-621.
15. FB Hu MJ Stampfer SM Haffner, et al. 2002 Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care. 25 7 1129 1134 10.2337/diacare.25.7.1129 12087009 (Pubitemid 41071162)
16. J Tuomilehto J Lindstrom JG Eriksson, et al. 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 1343 1350 1:STN:280:DC%2BD3M3kvFejsA%3D%3D 10.1056/NEJM200105033441801 11333990 (Pubitemid 32378388)
17. J Lindstrom P Ilanne-Parikka N Peltonen, et al. 2006 Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study Lancet 368 9548 1673 1679 10.1016/S0140- 6736(06)69701-8 17098085 (Pubitemid 46048554)
18. WC Knowler E Barrett-Connor SE Fowler, et al. 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 393 403 1:CAS:528:DC%2BD38XhtVWqurc%3D 10.1056/NEJMoa012512 11832527 (Pubitemid 34437694)
19. WC Knowler SE Fowler RF Hamman, et al. 2009 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 374 9702 1677 1686 10.1016/S0140-6736(09)61457-4 19878986
20. JT Devlin 1992 Effects of exercise on insulin sensitivity in humans Diabetes Care 15 1690 1693 1:STN:280:DyaK3s7gsFOrug%3D%3D 10.2337/diacare.15.11. 1690 1468302
21. XR Pan GW Li YH Hu, et al. 1997 Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Quing IGT and Diabetes Study Diabetes Care 20 537 544 1:STN:280:DyaK2s3ltFaqtw%3D%3D 10.2337/diacare.20.4.537 9096977
22. G Li P Zhang J Wang, et al. 2008 The long-term effect of lifestyle interventions to prevent diabetes in teh China Da Quing Diabetes Prevention Study; a 20-year follow-up study Lancet 371 9626 1783 1789 10.1016/S0140- 6736(08)60766-7 18502303 (Pubitemid 351697954)
23. CY Jeon RO Lokken FB Hu, et al. 2007 Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review Diabetes Care 30 3 744 752 10.2337/dc06-1842 17327354 (Pubitemid 46357402)
24. RF Hamman PR Wing SL Edelstein, et al. 2006 Effect of weight loss with lifestyle intervention on risk of diabetes Diabetes Care 29 9 2102 2107 10.2337/dc06-0560 16936160 (Pubitemid 44871194)
25. D Kirpichnikov SI McFarlane J Sowers 2002 Metformin: An Update Ann Intern Med 137 25 33 1:CAS:528:DC%2BD38Xls1enur4%3D 12093242
26. RE Ratner CA Christophi BE Metzger, et al. 2008 Prevention of diabetes in women with a hisotry of Getational Diabetes: Effects of metformin and lifestyle interventions J Clin Endocrinol Metab. 93 12 4774 4779 1:CAS:528: DC%2BD1cXhsVyqtbvO 10.1210/jc.2008-0772 18826999
27. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003, 26 (4): 977-980.
28. SR Salpeter MS Buckley JA Kahn, et al. 2008 Meta-analysis: metformin treatment in persons at risk for diabetes mellitus Am J Med 121 2 149 157 1:CAS:528:DC%2BD1cXhsleht78%3D 10.1016/j.amjmed.2007.09.016 18261504 e2 (Pubitemid 351199461)
29. F El-Atat J Nicasio L Clarke, et al. 2005 Beneficial Cardiovascular Effects of Thiazolidinediones Therapy 2 113 119 1:CAS:528:DC%2BD2MXhsFaqsLw%3D 10.2217/14750708.2.1.113
30. A Buchanon A Xiang R Peters, et al. 2002 Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women Diabetes 51 2796 2803 10.2337/diabetes.51.9.2796
31. DREAM trial investigators 2006 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial Lancet 368 1096 1105 10.1016/S0140- 6736(06)69420-8 (Pubitemid 44402668)
32. DeFronzo RA, for ACT NOW Study Group. ACTos NOW Study for the prevention of diabetes (ACT NOW) Study. Late breaking abstract at 68th Annual Scientific Session of the American Diabetes Association, 6 june 2008, San Francisco, CA
33. B Zinman S Harris J Neuman 2010 Low dose combination therapy with rosiglitazone and metfomin to prevent type 2 diabetes (CANOE trial): a double blind controlled study Lancet 376 103 11 1:CAS:528:DC%2BC3cXos1Chu7w%3D 10.1016/S0140-6736(10)60746-5 20605202
34. JL Chiasson RG Josse LA Leiter, et al. 1996 The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance Diabetes Care 19 1191 1194 10.2337/diacare.19.11.1190
35. JL Chiasson RG Josse R Gomis, et al. 2002 Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 359 2072 2077 1:CAS:528:DC%2BD38XkslGhs7g%3D 10.1016/S0140-6736(02)08905-5 12086760 (Pubitemid 34680970)
36. FA Van de Laar PL Lucassen RP Akkermans, et al. 2006 Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose Cochrane Database Syst Rev 4 CD005061 17054235
37. R Kawamori N Tajima Y Iwamato, et al. 2009 Voglibose for prevention of type 2 diabetes mellitus: a randomisd, double-blind trial in japanese individuals with impaired glucose tolerance Lancet 373 9675 1607 1614 1:CAS:528:DC%2BD1MXls1Khtr4%3D 10.1016/S0140-6736(09)60222-1 19395079
38. RR Holman SM Haffner IJ McMurray, et al. 2010 Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 16 1463 1476 1:CAS:528:DC%2BC3cXlt12ksLg%3D 10.1056/NEJMoa1001122 20228402
39. S Yusuf H Gerstein B Hoogwerf, et al. 2001 Ramipril and the development of diabetes JAMA 286 1882 1885 1:CAS:528:DC%2BD3MXns1yjurs%3D 10.1001/jama.286.15.1882 11597291
40. L Hansson LH Lindholm L Niskanen, et al. 1999 Effect of angiotensin-enzyme-inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial Lancet 353 611 616 1:CAS:528:DyaK1MXivVCls78%3D 10.1016/S0140-6736(98)05012-0 10030325 (Pubitemid 29087980)
41. The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group 2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2981 2997 10.1001/jama.288.23.2981 (Pubitemid 35471160)
42. B Dahlof RB Devereux SE Kjeldsen, et al. 2002 Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 1004 1010 10.1016/S0140-6736(02)08090-X 11937179 (Pubitemid 34286537)
43. EL Gillespie CM White M Kardas, et al. 2005 The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes Diabetes Care 28 2261 2266 1:CAS:528:DC%2BD2MXhtVGntr3J 10.2337/diacare.28.9.2261 16123505 (Pubitemid 41242483)
44. The DREAM trial investigators 2006 Effect of ramipril on the incidence of diabetes N Engl J Med 355 1551 1561 10.1056/NEJMoa065061 (Pubitemid 44550032)
45. JJ McMurray RR Holman SM haffner, et al. 2010 Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 1477 1:CAS:528:DC%2BC3cXlt12rsbo%3D 10.1056/NEJMcp0909392 20228403
46. SI McFarlane A Kumar JR Sowers 2003 Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease Am J Cardiol 91 H30 H37 10.1016/S0002-9149(03)00432-6 (Pubitemid 36724893)
47. EJ Henriken S Jacob 2003 Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition J Cell Physiol 196 171 179 10.1002/jcp.10294 (Pubitemid 36676455)
48. PO Carlsson C Berne L Jansson 1998 Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats Diabetologia 41 127 133 1:CAS:528:DyaK1cXosl2huw%3D%3D 10.1007/s001250050880 9498644 (Pubitemid 28088387)
49. A Scheen 2004 Prevention of Type 2 Diabetes Mellitus through Inhibition of the Renin-Angiotensin System Drugs 64 2537 2565 1:CAS:528: DC%2BD2MXhs1Omuw%3D%3D 10.2165/00003495-200464220-00004 15516153 (Pubitemid 39591650)
50. SB Heymsfield KR Segal J Hauptman, et al. 2000 Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults Arch Intern Med 160 1321 1326 1:CAS:528:DC%2BD3cXjslKnsLc%3D 10.1001/archinte.160.9.1321 10809036
51. JS Torgerson J Hauptman MN Boldrin, et al. 2004 Xenical in the prevention of diabetes in obese subjects (XENDOS) Study Diabetes Care 27 155 161 1:CAS:528:DC%2BD2cXmvV2jug%3D%3D 10.2337/diacare.27.1.155 14693982 (Pubitemid 38196725)
52. SI McFarlane R Muniyappa R Francisao, et al. 2002 Clinical Review 145: Pleiotropic effects of statins: lipid reduction and beyond J Clin Endocrinol Metab 87 1451 1458 1:CAS:528:DC%2BD38XivFKlsb0%3D 10.1210/jc.87.4.1451 11932263 (Pubitemid 34615220)
53. DJ Freeman J Norrie N Sattar, et al. 2001 Pravastatin and the Development of Diabetes Mellitus: Evidence of a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 357 362 1:CAS:528: DC%2BD3MXhtF2ks7c%3D 11157685
54. VG Athyros K Tziomalos A Karagiannis, et al. 2010 Lipid-lowering agents and new onset diabetes mellitus Expert Opin Pharmacother 11 12 1965 1970 1:CAS:528:DC%2BC3cXptVantLk%3D 10.1517/14656566.2010.489553 20486831
55. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator receptor (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005, 16; 4:14.
56. A Rovellini D Sommariva A Branchi, et al. 1992 Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia Pharmacol Res. 25 237 45 1:STN:280: DyaK38zptVaqug%3D%3D 10.1016/S1043-6618(05)80072-6 1518767
57. A Tenenbaum M Motro EZ Fisman, et al. 2005 Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients Eur Heart J. 26 2032 8 1:CAS:528:DC%2BD2MXhtF2qtbnN 10.1093/eurheartj/ehi310 15872029 (Pubitemid 41435721)
58. A Tenenbaum M Motro E Fisman, et al. 2004 Peroxisome Proliferator- Activated Receptor Ligand Bezafibrate for prevention of type 2 Diabetes Mellitus in patients with coronary artery disease Circulation 109 2197 2202 1:CAS:528:DC%2BD2cXjs1eisrY%3D 10.1161/01.CIR.0000126824.12785.B6 15123532 (Pubitemid 38656105)
59. L Sjostrom AK Lindroos M Peltonen, et al. 2004 Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery N Eng J Med 351 2683 2693 10.1056/NEJMoa035622 (Pubitemid 39665322)
60. CD Sjostrom 2003 Surgery as an intervention for obesity. Results from the Swedish Obese Subjects Study Growth Hormone and IGF Research 13 S22 S26 10.1016/S1096-6374(03)00049-2 12914721 (Pubitemid 37161651)
61. WJ Pories MS Swanson KG MacDonald, et al. 1995 Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus Annals of Surgery 222 339 350 1:STN:280:DyaK2Mvgsl2ltA%3D%3D 10.1097/00000658-199509000-00011 7677463
62. SD Long K O'Brien KG MacDonald Jr, et al. 1994 Weight loss in severely obese subjects prevents the prevention of impaired glucose tolerance test to type II Diabetes A longitudinal interventional study. Diabetes care 17 372 375 1:STN:280:DyaK2czktFSjsw%3D%3D